Global Angioplasty Balloons Market - Size and Forecast Analysis, 2021-2035

Global Angioplasty Balloons Market Size is expected to reach USD 20.3 Billion by 2035 from USD 4.61 Billion in 2024, with a CAGR of around 14.4% between 2024 and 2035. The global angioplasty balloons market is primarily driven by the rising prevalence of cardiovascular diseases and advancements in medical technologies. The increasing number of patients with coronary artery diseases is fueling the demand for angioplasty balloons, as these devices are commonly used in procedures like percutaneous coronary interventions (PCI). For instance, balloon angioplasty is regularly performed in hospitals to treat blocked arteries, improving blood flow in patients with heart conditions. Additionally, technological advancements, such as drug-coated balloons (DCBs), have enhanced treatment effectiveness. These balloons release medication to prevent restenosis, a common issue after standard balloon angioplasty. However, the high cost of advanced angioplasty balloons remains a significant restraint, limiting access to these therapies in low-income regions. Despite this, opportunities for market growth are abundant. One opportunity lies in the increasing adoption of minimally invasive surgeries, where angioplasty balloons are essential for reducing recovery times and improving patient outcomes. Another opportunity is the growing focus on expanding healthcare access in emerging markets, where the number of cardiovascular disease cases is rising. This trend has led to hospitals and clinics in regions like Asia and Latin America adopting more angioplasty balloon treatments, driving market expansion.

Driver: Rising Cardiovascular Disease Fuels Market Growth

The increasing prevalence of cardiovascular diseases is a key driver for the growth of the global angioplasty balloons market. As the number of people suffering from heart conditions continues to rise, especially in older populations, the demand for angioplasty procedures has surged. For example, hospitals in the United States and Europe are performing balloon angioplasty regularly to treat patients with atherosclerosis, a condition where plaque builds up in the arteries. These procedures help restore blood flow by using balloons to expand narrowed or blocked arteries. In addition, the growing incidence of lifestyle-related heart diseases, such as those caused by high cholesterol, obesity, and smoking, has increased the need for angioplasty interventions. In India, for instance, rising cases of hypertension and diabetes are contributing to a higher demand for angioplasty treatments. Balloon angioplasty is frequently used in these cases to manage blocked coronary arteries. Furthermore, the aging population in many countries has led to a rise in cardiovascular diseases, with patients often requiring repeated angioplasty procedures. As these conditions continue to escalate globally, hospitals and clinics are increasingly relying on angioplasty balloons to treat a variety of cardiovascular diseases, further driving the market’s growth.

Key Insights:

• The adoption rate of angioplasty balloons in cardiovascular procedures reached approximately 39.1% in North America in 2024.

• Hospitals and ambulatory surgery centers account for 75% and 38.8% of angioplasty balloon usage respectively in 2024.

• Over 15 million angioplasty balloon units were sold globally in 2023 across all applications.

• Johnson & Johnson and other key companies invested more than $50 million in R&D for angioplasty balloon technologies in 2023.

• Drug-eluting balloons held a market share of about 46.2% in 2024, reflecting growing adoption due to improved clinical outcomes.

• Asia-Pacific region showed a 4.6% annual growth rate in angioplasty balloon adoption from 2024 to 2030.

• The U.S. accounts for 90%+ of North America’s angioplasty balloon market share, driven by advanced healthcare infrastructure.

Segment Analysis:

The angioplasty balloons market is segmented by type and application, each playing a vital role in treatment strategies. Normal balloons are widely used for simple artery dilation procedures, offering a basic yet effective method for restoring blood flow. Drug eluting balloons (DEBs) have gained popularity for delivering medication directly to artery walls, reducing the risk of restenosis without needing permanent implants. For instance, DEBs are often used in treating small vessel disease, especially in diabetic patients. Cutting balloons are designed with small blades that create controlled incisions in tough plaques, making them ideal for complex lesions where regular balloons may fail. Scoring balloons offer a similar benefit but use a scoring element to fracture plaque more evenly, reducing vessel trauma. In terms of application, hospitals remain the primary users of angioplasty balloons, handling the majority of emergency and planned cardiovascular interventions. Ambulatory surgical centers (ASCs) are increasingly adopting angioplasty procedures as they offer faster recovery and lower costs for patients requiring elective interventions. Laboratories specializing in cardiovascular research and device testing are also using various types of angioplasty balloons to develop new treatment protocols. As different types of balloons are chosen based on patient conditions, the market continues to evolve, providing better outcomes and treatment flexibility.

Regional Analysis:

The angioplasty balloons market is experiencing varied growth patterns across different regions. In North America, the high prevalence of obesity and diabetes is leading to an increased number of angioplasty procedures, with hospitals in Canada frequently using drug-eluting balloons for better patient outcomes. In Europe, advancements in cardiovascular treatment technologies are driving the demand, as seen in Germany where cutting balloons are being adopted to treat complex arterial blockages. The Asia Pacific region is witnessing rapid market expansion due to rising healthcare investments and a growing elderly population. In Japan, normal balloons are being used widely for routine coronary interventions, while India is seeing an increase in scoring balloon usage for treating severe cases. In the Middle East, improvements in healthcare infrastructure are encouraging more hospitals in Saudi Arabia to adopt advanced angioplasty procedures, including the use of drug-coated balloons for diabetic patients. Latin America is emerging as a promising market, with countries like Argentina expanding the availability of minimally invasive treatments. Here, ambulatory surgical centers are increasingly performing balloon angioplasties for patients seeking faster recovery and cost-effective care. Across all these regions, the growing focus on improving cardiovascular health is pushing the demand for diverse angioplasty balloon technologies, supporting continuous market growth.

Competitive Scenario:

The angioplasty balloons market is being significantly shaped by the efforts of leading medical device companies. Boston Scientific has received FDA approval for its AGENT™ Drug-Coated Balloon, the first coronary drug-coated balloon in the U.S., offering a new treatment option for coronary in-stent restenosis. Abbott has initiated first-in-human procedures with its investigational balloon-expandable transcatheter aortic valve implantation (TAVI) system, aiming to enhance treatment for symptomatic severe aortic stenosis. Spectranetics has obtained FDA 510(k) clearance for larger diameter AngioSculpt scoring balloons, designed to treat challenging lesions in hemodialysis access and peripheral arteries. B. Braun Melsungen AG, in collaboration with MEDRAD, is promoting the Paccocath® technology, a drug-eluting balloon treatment that delivers paclitaxel to diseased areas, aiming to keep arteries open wider over time. These developments reflect a broader trend among companies like Johnson & Johnson, Cardinal Health, Biotronik, Cook Medical, and Endocor, who are investing in innovative angioplasty balloon technologies to improve patient outcomes. The collective efforts of these companies are driving advancements in the market, offering new solutions for the treatment of cardiovascular diseases.​

Angioplasty Balloons Market Report Scope

The Global Angioplasty Balloons Market report is segmented as follows:

By Type,

• Normal Balloons
• Drug Eluting Balloons
• Cutting Balloons
• Scoring Balloons

By Application,

• ASCs
• Hospitals
• Lab

By Region,

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Argentina
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East and Africa

Key Market Players,

• Medtronic(US)
• Boston Scientific Corporation(US)
• Johnson & Johnson(US)
• Abbott(US)
• C.R. Bard Inc(US)
• Cardinal Health(Ireland)
• Spectranetics(US)
• Biotronik(Germany)
• Cook Medical Inc(US)
• Endocor(Germany)
• B. Braun Melsungen AG(Germany)